| 5 mins | 30 mins | Hourly | Daily | Weekly |
|---|---|---|---|---|
| SELL | SELL | SELL | SELL | SELL |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MA5 | 22.20▼ | 22.55▼ | 22.66▼ | 25.54▼ | 26.89▼ |
| MA10 | 22.22▼ | 22.85▼ | 23.54▼ | 26.48▼ | 27.21▼ |
| MA20 | 22.52▼ | 23.71▼ | 24.83▼ | 27.46▼ | 25.18▼ |
| MA50 | 22.83▼ | 25.37▼ | 26.23▼ | 27.55▼ | 24.31▼ |
| MA100 | 23.41▼ | 26.29▼ | 26.95▼ | 25.14▼ | 21.99▲ |
| MA200 | 24.68▼ | 27.10▼ | 28.15▼ | 24.60▼ | 21.43▲ |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MACD | -0.020▼ | -0.070▼ | -0.283▼ | -0.528▼ | -0.176▼ |
| RSI | 35.581▼ | 20.739▼ | 16.816▼ | 20.265▼ | 40.244▼ |
| STOCH | 26.705 | 17.120▼ | 18.849▼ | 19.509▼ | 52.379 |
| WILL %R | -82.703▼ | -94.978▼ | -96.107▼ | -96.955▼ | -93.597▼ |
| CCI | -50.488 | -141.920▼ | -101.963▼ | -317.377▼ | -123.816▼ |
| ▼ RSI&STOCH | $ACAD Oversold RSI + Stochastic | Set Alert |
| ▼ RSI | $ACAD RSI(14) Crossed Below 30 | Set Alert |
| ▼ MA | $ACAD MA(20) Crossed Below MA(50) | Set Alert |
| MA | $ACAD Price Crossed Below MA(200) | Set Alert |
| ▼ GAP | $ACAD Open Gap Down %3 | Set Alert |
| ▼ GAP | $ACAD Open Gap Down %2 | Set Alert |
| ▼ BREAK | $ACAD Price Breaks 60 Days Low | Set Alert |
| ▼ BREAK | $ACAD Price Breaks 30 Days Low | Set Alert |
| ▼ BREAK | $ACAD Price Breaks 20 Days Low | Set Alert |
| ▼ BREAK | $ACAD Price Breaks 10 Days Low | Set Alert |
|
Thursday, September 24, 2026 10:40 AM
Goldman Sachs analyst Salveen Richter reiterated a Sell rating and $17.00 price target on Acadia Pharmaceuticals (NASDAQ: ACAD).The analyst comments "ACAD's Phase 2 study of 5-HT2A inverse ...
|
|
Thursday, September 24, 2026 09:20 AM
TD Cowen analyst Ritu Baral reiterated a Buy rating and $37.00 price target on Acadia Pharmaceuticals (NASDAQ: ACAD).The analyst comments "Remlifanserin Ph2 ...
|
|
Thursday, September 24, 2026 08:25 AM
Shares of Acadia Pharmaceuticals (NASDAQ:ACAD) fell more than 9% Thursday morning after the company reported mixed Phase 2 results for remlifanserin, its experimental treatment for Alzheimer's disease ...
|
| date | open | high | low | close | volume |
|---|---|---|---|---|---|
| 24/09/26 | 24.21 | 24.22 | 22.00 | 22.19 | 6,183,803 |
| 23/09/26 | 26.41 | 26.51 | 24.93 | 25.43 | 1,305,764 |
| 22/09/26 | 26.65 | 26.855 | 26.32 | 26.41 | 1,442,433 |
| 21/09/26 | 27.43 | 27.43 | 26.34 | 26.395 | 1,351,906 |
| 18/09/26 | 27.37 | 27.475 | 26.73 | 27.29 | 5,482,709 |
| 17/09/26 | 27.78 | 28.06 | 27.29 | 27.45 | 1,276,291 |
| 16/09/26 | 26.75 | 27.60 | 26.66 | 27.54 | 1,405,147 |
| 15/09/26 | 27.51 | 27.51 | 26.64 | 26.76 | 1,109,167 |
| 14/09/26 | 27.995 | 28.10 | 27.3817 | 27.52 | 1,628,500 |
| 11/09/26 | 27.98 | 28.24 | 27.74 | 27.83 | 1,152,025 |
|
|
||||
|
|
||||
|
|